As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.
21 Analysts have issued a Janux Therapeutics Inc forecast:
21 Analysts have issued a Janux Therapeutics Inc forecast:
Jun '25 |
+/-
%
|
||
Revenue | 0.44 0.44 |
97%
97%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -143 -143 |
124%
124%
|
EBIT (Operating Income) EBIT | -145 -145 |
120%
120%
|
Net Profit | -106 -106 |
140%
140%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.
Head office | United States |
CEO | David Campbell |
Employees | 103 |
Founded | 2017 |
Website | www.januxrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.